Rigel Pharmaceuticals, Inc.
HealthcareNASDAQ:RIGL · NASDAQ Global Select
+$0.77 today
Vol 0.24M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
93.8%
avg 50.0%
ROIC
28.2%
avg -45.5%
ROA
71.5%
avg -28.1%
Analysis
ROE is currently the strongest return metric at 93.8% versus its period average of 50.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Raul R. Rodriguez | President, Chief Executive Officer & Director | $1.47M | — | 65 | $279,593.00 | 1.51% |
David A. Santos | Executive Vice President & Chief Commercial Officer | $865,325.00 | — | 63 | $61,996.00 | 0.34% |
Lisa Rojkjaer | Executive Vice President & Chief Medical Officer | $863,896.00 | — | 60 | $34,003.00 | 0.18% |
Dean L. Schorno | Executive Vice President & Chief Financial Officer | $856,130.00 | — | 63 | $78,790.00 | 0.43% |
Raymond J. Furey | Executive Vice President, Chief Compliance Officer, General Counsel & Corporate Secretary | $803,223.00 | — | 58 | $50,936.00 | 0.28% |
Joseph Lasaga | Executive Vice President & Chief Business Officer | — | — | 51 | $43,750.00 | 0.24% |
Tarek Sallam | Vice President of Marketing | — | — | — | — | — |
Julie Patel | Senior Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$218,365.00
Net Sentiment
$218,365.00
Net selling
Most Active
Ali-Jackson Kamil
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| May 26, 2026 | Ali-Jackson Kamil Direct | Sell | 2.5K | $29.17 | $72,925.00 | |
| Feb 20, 2026 | MOOS WALTER H Direct | Sell | 4.0K | $36.36 | $145,440.00 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $218,365.00 over the last 12 months. That adds up to net selling of $218,365.00. Ali-Jackson Kamil was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +134.2% | +18.9% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +134.2% over three years. Forward estimates point to Revenue at +18.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Omeros Corporation
NASDAQ:OMER
$632.20M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages RIGL?
Rigel Pharmaceuticals, Inc. (RIGL) lists 8 active executives. The top listed executive is David A. Santos, Executive Vice President & Chief Commercial Officer.
Are RIGL insiders buying or selling?
Recent insider activity shows net buying of $13.55M.
Explore More
Continue the stock analysis
Jump to another research area for this company.